Congenica secures new two-year contract with Hong Kong Genome Project
Congenica announces a two-year extension to their contract with the Hong Kong Genome Project (HKGP).
Congenica and myTomorrows announce partnership to advance Precision Oncology by facilitating rapid access to clinical trials
Congenica and myTomorrows have partnered to expedite access to precision oncology for cancer patients worldwide.
Congenica co-founder Professor Richard Durbin awarded the 39th International Prize for Biology
Congenica Informatics Director Richard Durbin has been awarded the International Prize for Biology by the Japan Society of the Promotion of Science.
Congenica co-founder Professor Matt Hurles appointed as Director of the Wellcome Sanger Institute
Co-founder and Scientific Director at Congenica, Professor Matt Hurles, has today been appointed as Director of The Wellcome Trust Sanger Institute.
Congenica announces Early Access Program for its novel Precision Oncology Solution
Congenica launches early access program for its new CE-IVD Precision Oncology Solution
Congenica approved as supplier on Government G-Cloud 13 framework
Congenica is an approved supplier on UK Government G-Cloud 13 framework
Congenica awarded European contract to develop NGS analysis workflow in oncology
Congenica awarded a contract to develop standardised NGS workflows in oncology for a group of 7 Central European hospitals by the Medical University Graz
Congenica and FDB collaborate to incorporate PGx into Clinical Decision Support Systems
Congenica and FDB announce a collaboration agreement to develop the delivery of pharmacogenomics (PGx) results into point of care prescribing.
Congenica gives employees ‘cost of living’ bonus
Congenica employees receive one off bonus to help with increases in cost of living
Congenica announces partnership with Avesthagen
Congenica announces a partnership with Avesthagen, strengthenening Congenica’s presence in India
Collaborative development of novel Precision Oncology Solution
Congenica has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution.
Congenica appoints Robert Denison as CEO
Congenica announces the appointment of Robert Denison as Chief Executive Officer (CEO). He will also join the Board of the company.